Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients.

Dyspnea is a common emergency department (ED) complaint, and it may be associated with significant mortality risk. We studied 599 dyspneic subjects enrolled in an ED. At 1 year, the role of inflammatory markers (including C-reactive protein [CRP]) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) as independent predictors of mortality was assessed. By 1 year, 91 subjects (15.2%) had died. Among patients who died, the median CRP concentration at admission was significantly higher than in survivors: 47.2 mg/L (449.5 nmol/L; interquartile range [IQR], 10.2-101.9 mg/L [97.1-970.5 nmol/L]) vs 7.25 mg/L (69.5 nmol/L; IQR, 2.2-29.6 mg/L [21.0-281.9 nmol/L]; P < .001). For 1-year mortality, CRP had an area under the receiver operating characteristic curve of 0.76 (95% confidence interval [CI], 0.69-0.80; P < .001). In multivariable analysis, a CRP concentration greater than 14 mg/L was a strong predictor of mortality at 1 year (hazard ratio, 2.47; 95% CI, 1.51-4.02; P < .001). In multivariable models, CRP and NT-proBNP demonstrated independent and additive prognostic value. Among dyspneic patients, CRP levels are significantly associated with mortality at 1 year and show additive value to natriuretic peptide testing for prognosis.

[1]  A. Abdellaoui,et al.  C-reactive protein (CRP) as a marker in peripheral vascular disease. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[2]  John G F Cleland,et al.  Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. , 2007, American heart journal.

[3]  M. Christ-Crain,et al.  Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia , 2007, BMC infectious diseases.

[4]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[5]  N. Inoue,et al.  Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. , 2006, Cardiovascular & hematological disorders drug targets.

[6]  S. Ignjatović,et al.  Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. , 2006, International heart journal.

[7]  John R Hurst,et al.  Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[8]  U. Singh,et al.  C-reactive protein and the vascular endothelium: implications for plaque instability. , 2006, Journal of the American College of Cardiology.

[9]  C. Mueller,et al.  Inflammation and long-term mortality in acute congestive heart failure. , 2006, American heart journal.

[10]  R. Tieleman,et al.  Statins associated with reduced mortality in patients admitted for congestive heart failure. , 2006, Journal of cardiac failure.

[11]  H. Krumholz,et al.  Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure , 2006, Circulation.

[12]  C. Camargo,et al.  Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.

[13]  S. Anker,et al.  The importance of the gastrointestinal system in the pathogenesis of heart failure. , 2005, European heart journal.

[14]  T. Dwolatzky,et al.  Acute phase response detection and quantitation at the point of care in older adults with acute bacterial infections. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[16]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[17]  A. Mendez,et al.  Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. , 2005, The American journal of cardiology.

[18]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[19]  W. Yin,et al.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.

[20]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[21]  K. Sliwa,et al.  Therapy of Ischemic Cardiomyopathy With the Immunomodulating Agent Pentoxifylline: Results of a Randomized Study , 2004, Circulation.

[22]  G. Schuler,et al.  Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure , 2003, European journal of heart failure.

[23]  Z. Vered,et al.  Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. , 2003, The American journal of cardiology.

[24]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[25]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[26]  D. Mari,et al.  Chronic heart failure and the immune system , 2002, Clinical reviews in allergy & immunology.

[27]  R. Holubkov,et al.  Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[29]  E. Antman,et al.  C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.

[30]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[31]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.